Journal article
Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity
Frontiers in immunology, v 11, pp 1055-1055
16 Jun 2020
PMID: 32655548
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Dengue is one of the most frequently transmitted mosquito-borne diseases in the world, which creates a significant public health concern globally, especially in tropical and subtropical countries. It is estimated that more than 390 million people are infected with dengue virus each year and around 96 million develop clinical pathologies. Dengue infections are not only a health problem but also a substantial economic burden. To date, there are no effective antiviral therapies and there is only one licensed dengue vaccine that only demonstrated protection in the seropositive (Immune), naturally infected with dengue, but not dengue seronegative (Naive) vaccines. In this review, we address several immune components and their interplay with the dengue virus. Additionally, we summarize the literature pertaining to current dengue vaccine development and advances. Moreover, we review some of the factors affecting vaccine responses, such as the pre-vaccination environment, and provide an overview of the significant challenges that face the development of an efficient/protective dengue vaccine including the presence of multiple serotypes, antibody-dependent enhancement (ADE), as well as cross-reactivity with other flaviviruses. Finally, we discuss targeting T follicular helper cells (Tfh), a significant cell population that is essential for the production of high-affinity antibodies, which might be one of the elements needed to be specifically targeted to enhance vaccine precision to dengue regardless of dengue serostatus.
Metrics
Details
- Title
- Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity
- Creators
- Abdullah M. Izmirly - King Abdulaziz UniversitySana O. Alturki - King Abdulaziz UniversitySawsan O. Alturki - King Abdulaziz UniversityJennifer Connors - Drexel UniversityElias K. Haddad - Drexel University
- Publication Details
- Frontiers in immunology, v 11, pp 1055-1055
- Publisher
- Frontiers Media Sa
- Number of pages
- 15
- Grant note
- U19 AI128910; AI125202 / NIH, Human Immune Project Consortium (HIPC); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine; Infectious Diseases (and HIV Medicine); Drexel University
- Web of Science ID
- WOS:000546121200001
- Scopus ID
- 2-s2.0-85087130857
- Other Identifier
- 991020099436304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Immunology